NCT05908968

Brief Summary

This pilot study examined the effects of ELO water, a commercially-available oxygen-enriched drinking water, on wound healing in patients with diabetic foot ulcers over 12 weeks.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
16

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Sep 2017

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 19, 2017

Completed
2.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 30, 2019

Completed
1.6 years until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2021

Completed
1.9 years until next milestone

First Submitted

Initial submission to the registry

June 4, 2023

Completed
14 days until next milestone

First Posted

Study publicly available on registry

June 18, 2023

Completed
Last Updated

June 18, 2023

Status Verified

June 1, 2023

Enrollment Period

2.2 years

First QC Date

June 4, 2023

Last Update Submit

June 16, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • Reduction in wound area

    Absolute and percentage reduction in wound area

    12 weeks

Secondary Outcomes (1)

  • Complete wound closure

    12 weeks

Study Arms (1)

Drinking ELO water

EXPERIMENTAL

Drinking 1.5 litres of ELO water daily

Dietary Supplement: ELO water

Interventions

ELO waterDIETARY_SUPPLEMENT

Drinking 1.5 litres daily of ELO water for 12 weeks

Drinking ELO water

Eligibility Criteria

Age21 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • type 2 diabetes and haemoglobin A1c (HbA1c) at screening of 7.0-10.0% on oral glucose-lowering medication and/or insulin at a stable dose for the last three months

You may not qualify if:

  • pregnant or lactating
  • conditions which would independently worsen ulcer healing such as severe peripheral vascular disease or varicose veins
  • immunosuppressive therapy
  • comorbidities necessitating fluid restriction such as renal, liver or cardiac failure.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Joan Khoo

Singapore, 529889, Singapore

Location

Related Publications (3)

  • Schreml S, Szeimies RM, Prantl L, Karrer S, Landthaler M, Babilas P. Oxygen in acute and chronic wound healing. Br J Dermatol. 2010 Aug;163(2):257-68. doi: 10.1111/j.1365-2133.2010.09804.x. Epub 2010 Apr 15.

  • Sun XK, Li R, Yang XL, Yuan L. Efficacy and safety of topical oxygen therapy for diabetic foot ulcers: An updated systematic review and meta-analysis. Int Wound J. 2022 Dec;19(8):2200-2209. doi: 10.1111/iwj.13830. Epub 2022 May 5.

  • Khoo J, Hagemeyer CE, Henstridge DC, Kumble S, Wang TY, Xu R, Gani L, King T, Soh SB, Puar T, Au V, Tan E, Tay TL, Kam C, Teo EK. Effects of water stably-enriched with oxygen as a novel method of tissue oxygenation on mitochondrial function, and as adjuvant therapy for type 2 diabetes in a randomized placebo-controlled trial. PLoS One. 2021 Jul 14;16(7):e0254619. doi: 10.1371/journal.pone.0254619. eCollection 2021.

MeSH Terms

Conditions

Diabetic Foot

Condition Hierarchy (Ancestors)

Diabetic AngiopathiesVascular DiseasesCardiovascular DiseasesFoot UlcerLeg UlcerSkin UlcerSkin DiseasesSkin and Connective Tissue DiseasesDiabetes ComplicationsDiabetes MellitusEndocrine System DiseasesDiabetic Neuropathies

Study Officials

  • Joan Khoo

    Changi General Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Model Details: Adults with type 2 diabetes and diabetic foot ulcer which has not healed with conventional therapy for at least 30 days prior to recruitment
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 4, 2023

First Posted

June 18, 2023

Study Start

September 19, 2017

Primary Completion

November 30, 2019

Study Completion

June 30, 2021

Last Updated

June 18, 2023

Record last verified: 2023-06

Data Sharing

IPD Sharing
Will not share

Locations